Karyopharm to present new selinexor data at the 2022 american society of clinical oncology annual meeting

– encouraging initial data observed in phase 1/2 study of selinexor in combination with ruxolitinib in treatment-naÏve myelofibrosis, including favorable tolerability with no dose limiting toxicities and 75% of evaluable patients demonstrating ≥35% spleen volume reduction (svr 35) at week 12 – – fda grants orphan drug designation for selinexor for the treatment of myelofibrosis – – exploratory subgroup analyses from siendo trial in patients with endometrial cancer treated with selinexor as maintenance therapy identified p53 wild-type as a potentially important predictor of efficacy, with 10-month pfs improvement over placebo; no benefit was seen in patients with p53 mutant tumors – newton, mass., may 26, 2022 /prnewswire/ -- karyopharm therapeutics inc. (nasdaq: kpti), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced promising initial data from a phase 1/2 study evaluating selinexor in combination with ruxolitinib in patients with treatment-naÏve myelofibrosis and subgroup analyses and molecular classification data from the siendo study evaluating selinexor in endometrial cancer.
KPTI Ratings Summary
KPTI Quant Ranking